A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases.

Objective: To evaluate the safety of etanercept in patients with rheumatoid arthritis (RA) and concomitant comorbidities.

Methods: The safety of etanercept (25 mg twice weekly) in RA patients with at least one comorbidity (i.e.